Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genzyme Gains EMA Approval for Framingham Plant | Contract Pharma

What are you searching for?

Sign in
Breaking News

Genzyme Gains EMA Approval for Framingham Plant

Aids manufacturing recovery for Fabrazyme

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme, a Sanofi company, received approval from the EMA for its manufacturing plant in Framingham, MA, for the production of Fabrazyme (agalsidase beta).

“This approval by the EMA represents an important milestone in our manufacturing recovery and path toward unconstrained supply for all patients,” said Genzyme’s president and chief executive officer, David Meeker. “Providing the Fabry community with consistent access to treatment, increasing our inventory of Fabrazyme and working toward all regulatory approvals of our Framingham plant are our highest priorities, and we remain on track to achieve all of these crucial goals.”

Additional global regulatory approvals, anticipated throughout the year, are needed to help return to normal supply levels of Fabrazyme globally.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters